Literature DB >> 27687190

Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures.

Joon Hwa Hong1, Hartzell V Schaff2, Rick A Nishimura3, Martin D Abel4, Joseph A Dearani1, Zhuo Li5, Steve R Ommen3.   

Abstract

BACKGROUND: Incidence and outcome of mitral valve (MV) surgery are unknown in patients with hypertrophic obstructive cardiomyopathy (HOCM) undergoing extended transaortic septal myectomy.
OBJECTIVES: This study sought to define indications and suitable operative strategy for mitral regurgitation (MR) in patients with HOCM.
METHODS: A total of 2,107 septal myectomy operations performed in adults from January 1993 to May 2014 at Mayo Clinic in Rochester, Minnesota, were retrospectively reviewed. Patients with prior MV operation and apical hypertrophic cardiomyopathy were excluded. Overall, 2,004 operations were performed in 1,993 patients.
RESULTS: Pre-operative MR was grade ≥3 (of 4) in 1,152 operations (57.5%). Systolic anterior motion of mitral leaflets caused the MR in most patients. However, intrinsic MV disease was identified pre-operatively in 99 patients, all of whom had MV surgery (with septal myectomy). In 1,905 operations, no intrinsic MV disease was identified pre-operatively; in 1,830 (96.1%), septal myectomy was performed without a direct MV procedure. For 75 patients, intrinsic MV disease discovered intraoperatively led to concomitant MV repair (86.7%) or replacement (13.3%). After isolated septal myectomy, the percentage of patients with MR grade ≥3 decreased from 54.3% to 1.7% (p = 0.001) on early post-operative echocardiography. Among 174 patients with concomitant MV surgery, late survival was superior with MV repair (n = 133 [76.4%]) versus replacement (10-year survival: 80.0% vs. 55.2%; p = 0.002).
CONCLUSIONS: In most patients with HOCM, MR related to systolic anterior motion of the MV is relieved through adequate myectomy. Concomitant MV surgery is rarely necessary unless intrinsic MV disease is present. When MV procedures are required, repair is preferred because of improved survival compared with replacement.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiomyopathy; mitral valve; regurgitation; survival

Mesh:

Year:  2016        PMID: 27687190     DOI: 10.1016/j.jacc.2016.07.735

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  22 in total

1.  Surgery for hypertrophic obstructive cardiomyopathy (HOCM): what to do with concomitant mitral insufficiency?

Authors:  Bruno J Messmer
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 2.  Management of the mitral valve in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Joon Hwa Hong; Anita Nguyen; Hartzell Vernon Schaff
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-05-07

3.  Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience.

Authors:  Rachel D Vanderlaan; Anna Woo; Anthony Ralph-Edwards
Journal:  Ann Cardiothorac Surg       Date:  2017-07

4.  Alcohol septal ablation: in which patients and why?

Authors:  Paolo Spirito; Jessica Rossi; Barry J Maron
Journal:  Ann Cardiothorac Surg       Date:  2017-07

Review 5.  Surgical treatment for hypertrophic cardiomyopathy: a historical perspective.

Authors:  Dustin Hang; Anita Nguyen; Hartzell V Schaff
Journal:  Ann Cardiothorac Surg       Date:  2017-07

6.  Does the Flow Know? Mitral Regurgitant Jet Direction and Need for Valve Repair in Hypertrophic Obstructive Cardiomyopathy.

Authors:  Ehud Schwammenthal; Albert A Hagège; Robert A Levine
Journal:  J Am Soc Echocardiogr       Date:  2019-03       Impact factor: 5.251

Review 7.  Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Authors:  Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

8.  Minimally invasive trans-mitral septal myectomy for diffuse-type hypertrophic obstructive cardiomyopathy.

Authors:  Taichi Sakaguchi; Toshinori Totsugawa; Kentaro Tamura; Arudo Hiraoka; Genta Chikazawa; Hidenori Yoshitaka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-03-16

Review 9.  Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.

Authors:  C Charles Jain; Darrell B Newman; Jeffrey B Geske
Journal:  Curr Cardiol Rep       Date:  2019-10-31       Impact factor: 2.931

10.  Outcome of mitral valve repair or replacement for non-ischemic mitral regurgitation: a systematic review and meta-analysis.

Authors:  Qianqian Fan; Xiaoguang Li; Guilan Cao; Puliang Yu; Fengxiao Zhang
Journal:  J Cardiothorac Surg       Date:  2021-06-15       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.